J u m p t o c o n t e n t
M a i n m e n u
M a i n m e n u
N a v i g a t i o n
● M a i n p a g e ● C o n t e n t s ● C u r r e n t e v e n t s ● R a n d o m a r t i c l e ● A b o u t W i k i p e d i a ● C o n t a c t u s ● D o n a t e
C o n t r i b u t e
● H e l p ● L e a r n t o e d i t ● C o m m u n i t y p o r t a l ● R e c e n t c h a n g e s ● U p l o a d f i l e
S e a r c h
Search
A p p e a r a n c e
● C r e a t e a c c o u n t ● L o g i n
P e r s o n a l t o o l s
● C r e a t e a c c o u n t ● L o g i n
P a g e s f o r l o g g e d o u t e d i t o r s l e a r n m o r e ● C o n t r i b u t i o n s ● T a l k
( T o p )
1 C o n t r a i n d i c a t i o n s
2 A d v e r s e e f f e c t s
3 I n t e r a c t i o n s
4 P h a r m a c o l o g y
5 H i s t o r y
6 R e f e r e n c e s
T o g g l e t h e t a b l e o f c o n t e n t s
N e t u p i t a n t / p a l o n o s e t r o n
3 l a n g u a g e s
● ଓ ଡ ଼ ି ଆ ● У к р а ї н с ь к а ● T i ế n g V i ệ t
E d i t l i n k s
● A r t i c l e ● T a l k
E n g l i s h
● R e a d ● E d i t ● V i e w h i s t o r y
T o o l s
T o o l s
A c t i o n s
● R e a d ● E d i t ● V i e w h i s t o r y
G e n e r a l
● W h a t l i n k s h e r e ● R e l a t e d c h a n g e s ● U p l o a d f i l e ● S p e c i a l p a g e s ● P e r m a n e n t l i n k ● P a g e i n f o r m a t i o n ● C i t e t h i s p a g e ● G e t s h o r t e n e d U R L ● D o w n l o a d Q R c o d e ● W i k i d a t a i t e m
P r i n t / e x p o r t
● D o w n l o a d a s P D F ● P r i n t a b l e v e r s i o n
A p p e a r a n c e
F r o m W i k i p e d i a , t h e f r e e e n c y c l o p e d i a
Netupitant/palonosetron , sold under the brand name Akynzeo , is a fixed-dose combination medication used for the prevention of acute and delayed chemotherapy-induced nausea and vomiting .[7] [9] Helsinn Therapeutics . Netupitant is an NK 1 palonosetron is a 5-HT3 .[10]
The capsules contain netupitant and palonosetron hydrochloride . The intravenous version is a combination of fosnetupitant chloride hydrochloride and palonosetron hydrochloride .[11] [7] [8]
Contraindications
[ edit ]
Netupitant/palonosetron may be contraindicated during pregnancy.[12] [1] [13]
Adverse effects
[ edit ]
The most common side effects include headache, weakness, fatigue, upset stomach, constipation , and skin redness.[7] Palonosetron#Adverse effects ); no common adverse effects can be attributed to netupitant.[12]
Interactions
[ edit ]
Pharmacology
[ edit ]
History
[ edit ]
Netupitant/palonosetron was approved for use in the United States in October 2014.[14] [8] fosnetupitant in place of netupitant, was approved in the United States in April 2018.[15] [11]
References
[ edit ]
^ "Prescription medicines: registration of new chemical entities in Australia, 2015" . Therapeutic Goods Administration (TGA) . 21 June 2022. Archived from the original on 10 April 2023. Retrieved 10 April 2023 .
^ "Archived copy" (PDF) . Archived (PDF) from the original on 10 June 2022. Retrieved 10 June 2022 .{{cite web }}: CS1 maint: archived copy as title (link )
^ "Cancer therapies" . Health Canada Archived from the original on 16 June 2024. Retrieved 13 April 2024 .
^ "Akynzeo 300 mg/0.5 mg hard capsules - Summary of Product Characteristics (SmPC)" . (emc) . 11 February 2020. Archived from the original on 19 March 2020. Retrieved 19 March 2020 .
^ a b c d "Akynzeo- netupitant and palonosetron capsule; Akynzeo- fosnetupitant and palonosetron injection" . DailyMed . 28 May 2020. Archived from the original on 18 October 2020. Retrieved 18 July 2020 .
^ a b c "Akynzeo EPAR" . European Medicines Agency (EMA)Archived from the original on 19 March 2020. Retrieved 19 March 2020 .
^ "FDA approves Akynzeo for nausea and vomiting associated with cancer chemotherapy" (Press release). U.S. Food and Drug Administration (FDA). 10 October 2014. Archived from the original on 1 February 2017. Retrieved 16 December 2019 .
^ "Akynzeo: Summary of Product Characteristics" (PDF) . European Medicines Agency . Archived (PDF) from the original on 26 June 2016. Retrieved 12 July 2016 .
^ a b "Drug Trials Snapshots: Akynzeo" . U.S. Food and Drug Administration (FDA) . 11 May 2018. Archived from the original on 24 January 2020. Retrieved 19 March 2020 .
^ a b Haberfeld H, ed. (2015). Austria-Codex (in German). Vienna: Österreichischer Apothekerverlag. Akynzeo 300 mg / 0,5 mg Hartkapseln.
^ "Fosnetupitant / palonosetron (Akynzeo for Injection) Use During Pregnancy" . Drugs.com . 22 October 2018. Archived from the original on 19 March 2020. Retrieved 19 March 2020 .
^ "Drug Approval Package: Akynzeo (Netupitant and Palonosetron) Capsules NDA #205718" . U.S. Food and Drug Administration (FDA) . 7 November 2014. Archived from the original on 19 March 2020. Retrieved 19 March 2020 .
^ "Drug Approval Package: Akynzeo (fosnetupitant and palonosetron) Injection" . U.S. Food and Drug Administration (FDA) . 31 May 2018. Archived from the original on 19 March 2020. Retrieved 19 March 2020 .
R e t r i e v e d f r o m " https://en.wikipedia.org/w/index.php?title=Netupitant/palonosetron&oldid=1232894456 " C a t e g o r i e s : ● A n t i e m e t i c s ● C o m b i n a t i o n d r u g s H i d d e n c a t e g o r i e s : ● C S 1 m a i n t : a r c h i v e d c o p y a s t i t l e ● C S 1 G e r m a n - l a n g u a g e s o u r c e s ( de ) ● A r t i c l e s w i t h s h o r t d e s c r i p t i o n ● S h o r t d e s c r i p t i o n m a t c h e s W i k i d a t a ● U s e d m y d a t e s f r o m A p r i l 2 0 2 4 ● D r u g s w i t h n o n - s t a n d a r d l e g a l s t a t u s ● A r t i c l e s w i t h o u t E B I s o u r c e ● C h e m i c a l p a g e s w i t h o u t C h e m S p i d e r I D ● C h e m i c a l p a g e s w i t h o u t D r u g B a n k i d e n t i f i e r ● A r t i c l e s w i t h o u t I n C h I s o u r c e ● A r t i c l e s w i t h o u t U N I I s o u r c e ● A r t i c l e s c o n t a i n i n g u n v e r i f i e d c h e m i c a l i n f o b o x e s ● D r u g s t h a t a r e a c o m b i n a t i o n o f c h e m i c a l s
● T h i s p a g e w a s l a s t e d i t e d o n 6 J u l y 2 0 2 4 , a t 0 5 : 2 9 ( U T C ) . ● T e x t i s a v a i l a b l e u n d e r t h e C r e a t i v e C o m m o n s A t t r i b u t i o n - S h a r e A l i k e L i c e n s e 4 . 0 ;
a d d i t i o n a l t e r m s m a y a p p l y . B y u s i n g t h i s s i t e , y o u a g r e e t o t h e T e r m s o f U s e a n d P r i v a c y P o l i c y . W i k i p e d i a ® i s a r e g i s t e r e d t r a d e m a r k o f t h e W i k i m e d i a F o u n d a t i o n , I n c . , a n o n - p r o f i t o r g a n i z a t i o n . ● P r i v a c y p o l i c y ● A b o u t W i k i p e d i a ● D i s c l a i m e r s ● C o n t a c t W i k i p e d i a ● C o d e o f C o n d u c t ● D e v e l o p e r s ● S t a t i s t i c s ● C o o k i e s t a t e m e n t ● M o b i l e v i e w
